Article
13 October 2025 - by Samantha D’Anna, Lauren Loney
We present key considerations to help dental insurers evaluate the impacts on claims and potentially negative oral health effects.
Article
11 August 2025 - by Samantha D’Anna, Nicole Synnott, Shelby R. Weber
Medicare drug benefits: We highlight nine concepts for life science companies to better understand coverage and facilitate conversations with other stakeholders.
Article
11 February 2025 - by Tracy Margiott, Samantha D’Anna, Sergey Rubin, Katie McBride
We estimate that proposed frozen formulary legislation could increase payer prescription drug costs by as much as $125 million in 2024 and $270 million in 2028.
Article
10 September 2024 - by Tory Carver, Tracy Margiott, Samantha D’Anna
We share the results of our count of pharmacy services administrative organizations for the Pharmaceutical Care Management Association.
Article
04 June 2024 - by Tory Carver, Samantha D’Anna, Tracy Margiott
We examine the 2021 retail pharmacy reimbursement in Medicare Part D by drug and pharmacy type.
Article
02 May 2024 - by Samantha D’Anna, Tyler Engel, Katherine M. Holcomb
2024 brings significant changes to the Medicare Part D program, resulting in larger-than-average shifts in member enrollment.
Article
07 March 2023 - by Tory Carver, Samantha D’Anna, Tracy Margiott
Proposed legislation would require PBMs to publish Medicare Part D rebate information, potentially altering the strategies of stakeholders.
Article
09 November 2022 - by Samantha D’Anna, Nolan Kurtz
We look at the metrics of Medicare beneficiaries with prescription drug coverage across ethnicity, income, and education level in the individual Part D market.
Video
31 August 2022 - by Kevin Pierce, Jake K. Klaisner, Michelle (Klein) Robb, Samantha D’Anna
After more than a year of deliberation, the U.S. Senate and the U.S House of Representatives passed the Inflation Reduction Act of 2022, and it was signed into law by the President on August 16, 2022. What does this mean for healthcare?
Article
22 July 2022 - by Michelle (Klein) Robb, Kevin Pierce, Samantha D’Anna, Jake K. Klaisner
We examine key provisions of Senator Schumer and the Senate Finance Committee’s new Prescription Drug Pricing Reform language, and compare with the Build Back Better Act’s previous version.
